Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast

Trastuzumab Deruxtecan in Previously Treated HER2-Low trastuzumab Trastuzumab has also been shown to penetrate an impaired blood–brain barrier to a limited degree, such as during radiotherapy, and intrathecal delivery of trastuzumab Trastuzumab exerts an antitumour activity and is used in the treatment of HER2-positive breast cancer HER2 protein overexpression is observed in 20%-30% of

trastuzumab trastuzumab A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2